Published within
|«
«
|
...
|
9
|
10
|
11
|
12
|
13
|
14
|
15
|
16
|
17
|
...
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
Expert View
|
Merck & Co has announced that it will be trialing a trivalent HIV vaccine in a Phase II proof-of-concept study with the US HIV Trials Network (HVTN). Despite nearly two decades of investigation, an effective HIV vaccine seems no nearer fruition. However, as Datamonitor's Laura Harris explains, more sophisticated immune targeting may yet bring progress towards at least a partially effective drug...
Published By Datamonitor
|
25 Jan 2005 |
|
CommentWire
|
Eli Lilly [LLY] has announced an increase in revenues during Q4 2004 and a 10% increase in full year sales. However, revenues of its antipsychotic Zyprexa (olanzapine) fell significantly. A looming court decision on a US patent challenge to the drug further increases the uncertainty of Zyprexa's future. Even if Lilly wins in the courts, it is losing the battle in the antipsychotic market.
Published By Datamonitor
|
27 Jan 2005 |
|
CommentWire
|
Sanofi-Aventis has announced that a new formulation for Eloxatin (oxaliplatin) has been approved by the FDA. It is unlikely to increase the drug's patient base, but the new formulation should consolidate Sanofi-Aventis's position as one of the major players in colorectal cancer treatment.
Published By Datamonitor
|
07 Feb 2005 |
|
CommentWire
|
Shares in the UK's third-biggest drug manufacturer Shire slumped on news of Adderall XR's withdrawal in Canada, prompted after Shire provided information about 20 sudden deaths in patients taking Adderall XR for ADHD. The withdrawal from Canada will cause even bigger problems for Shire if the FDA chooses to follow Health Canada's lead, but at present this seems unlikely.
Published By Datamonitor
|
10 Feb 2005 |
|
CommentWire
|
Following submission of safety data from a Phase II clinical trial to the FDA, clearance has been granted for GenVec [GNVC] to resume clinical development of TNFerade in pancreatic adenocarcinoma patients. This is good news both for the company and for patients, since TNFerade holds real promise at this early stage for this notoriously hard-to-treat form of cancer.
Published By Datamonitor
|
14 Feb 2005 |
|
CommentWire
|
Biogen-IDEC [BIIB] and Elan [ELA.L] have announced that Tysabri has demonstrated significant improvements in disability progression and reduction in the rate of relapse in relapse-remitting multiple sclerosis (RRMS). The outlook for the drug is therefore extremely bright, and it could cannibalize revenues of rival RRMS products significantly. Tysabri may yet herald a new dawn in RRMS treatment.
Published By Datamonitor
|
18 Feb 2005 |
|
CommentWire
|
The European approval of Prialt (ziconotide) is the first for an intrathecal chronic pain drug for many years, and Prialt should now provide an effective and safe treatment for patients for whom other treatment has failed. However, given the limited number of patients for whom Prialt treatment will be suitable, the drug has limited market potential.
Published By Datamonitor
|
25 Feb 2005 |
|
Expert View
|
Biogen Idec and Elan have announced the voluntary suspension from sale and withdrawal from clinical trials of Tysabri, the companies' novel therapy for the treatment of relapse remitting multiple sclerosis (RRMS). This move has already slashed share prices of both companies. Even if Tysabri is relaunched with some form of black-box warning, doubts will surely linger over its long-term safety.
Published By Datamonitor
|
01 Mar 2005 |
|
Expert View
|
While the European Consensus Conference gained a consensus agreement for the treatment of HIV/HCV coinfection, the definition of best practice for the management of HIV/HBV remains clouded by the lack of data. However, this is certain to change with BMS' entecavir trial in HIV/HBV co-infected patients. Datamonitor's Brigitte de Lima reports...
Published By Datamonitor
|
08 Mar 2005 |
|
CommentWire
|
Renovis will be disappointed at the termination of a Phase II trial in PHN for its novel neuropathic pain therapy REN-1654. However, it should not give up hope: it is rightly planning to continue trials of the drug in sciatica, which could yet offer the access to the broader pain market. If Renovis can prove efficacy a marketing partnership for REN-1654 would be a logical next step for the firm.
Published By Datamonitor
|
10 Mar 2005 |
|
|«
«
|
...
|
9
|
10
|
11
|
12
|
13
|
14
|
15
|
16
|
17
|
...
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.